Kairos Pharma Ltd [AMEX: KAPA] price plunged by -20.24 percent to reach at -$0.34.
A sum of 5190411 shares traded at recent session while its average daily volume was at 5.11M shares. Kairos Pharma Ltd shares reached a high of $1.47 and dropped to a low of $1.21 until finishing in the latest session at $1.34.
The one-year KAPA stock forecast points to a potential upside of 83.91. The average equity rating for KAPA stock is currently 1.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Kairos Pharma Ltd [KAPA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KAPA shares is $8.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KAPA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Price to Book ratio for the last quarter was 3.96, with the Price to Cash per share for the same quarter was set at 0.15.
KAPA Stock Performance Analysis:
Kairos Pharma Ltd [KAPA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -25.56. With this latest performance, KAPA shares gained by 21.82% in over the last four-week period, additionally plugging by 42.55% over the last 6 months – not to mention a drop of -11.84% in the past year of trading.
Kairos Pharma Ltd (KAPA) Capital Structure & Debt Analysis
According to recent financial data for Kairos Pharma Ltd. ( KAPA), the Return on Equity (ROE) stands at -281.84%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -122.32%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Kairos Pharma Ltd’s Return on Invested Capital (ROIC) is -78.56%, showcasing its effectiveness in deploying capital for earnings.
Kairos Pharma Ltd (KAPA) Efficiency & Liquidity Metrics
Based on Kairos Pharma Ltd’s (KAPA) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Kairos Pharma Ltd (KAPA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Kairos Pharma Ltd. (KAPA) effectively leverages its workforce, generating an average of -$1177500.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 7.16% and a Quick Ratio of 7.16%, indicating strong ability to cover short-term liabilities.
KAPA Stock EPS
With the latest financial reports released by the company, Kairos Pharma Ltd posted -0.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.02/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.08. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for KAPA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Kairos Pharma Ltd go to -29.25%.
Kairos Pharma Ltd [KAPA] Institutonal Ownership Details
There are presently around $5.37%, or 8.72%% of KAPA stock, in the hands of institutional investors.
